Gene test could revolutionize prostate cancer screening
NCT ID NCT07265414
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether men with certain gene mutations (DRG) could benefit from a more tailored screening for prostate cancer. Researchers will test a combination of a blood test (PHI) and a special MRI scan in 320 men with or at risk for prostate cancer. The goal is to see if this approach finds cancers earlier and more accurately than the current PSA test and digital rectal exam.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Screening platform combining PHI blood test and mp-MRI scan
What this could lead to
If successful, this could lead to a more effective, personalized screening approach for men with DRG mutations, catching prostate cancer earlier and reducing both overdiagnosis and missed cases.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve outcomes. The approach may not prove better than standard screening, and results may not apply to all men.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS Humanitas Research Hospital
Milan, 20089, Italy